AIM: To investigate the effects of darapladib, a specific inhibitor of lipoprotein-associated phospholipase A2 (lp-PLA2), on inflammation and atherosclerotic formation in the low density lipoprotein receptor (LDLR)-deficient mice. METHODS: Six-week-old LDLR-deficient mice were fed an atherogenic high-fat diet for 17 weeks and then randomly divided into two groups. One group was administered darapladib (50 mg·kg(-1)·d(-1); po) for 6 weeks. The other group was administered saline as a control. Serum lipid levels were measured using the corresponding kits, and three inflammatory markers--interleukin-6 (IL-6), C reactive protein (hs-CRP), and platelet activating factor (PAF)--were determined using ELISA. Atherosclerotic plaque areas were stained with Sudan IV, and inflammatory gene expression at the lesions was evaluated using quantitative real-time PCR. RESULTS: The body weight and serum lipid level between the two groups were similar at the end of the dietary period. The serum lp-PLA2 activity, hs-CRP and IL-6 levels, however, were significantly reduced in the darpladib group. The inhibition of lp-PLA2 did not alter the serum PAF level. Furthermore, the plaque area, from the aortic arch to the abdominal aorta, was significantly reduced in the darpladib group. Additionally, the expression of inflammatory genes monocyte chemotactic protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) was significantly reduced at the lesions in the darapladib group. CONCLUSION: Inhibition of lp-PLA2 by darapladib decreases the inflammatory burden and atherosclerotic plaque formation in LDLR-deficient mice, which may be a new strategy for the treatment of atherosclerosis.
AIM: To investigate the effects of darapladib, a specific inhibitor of lipoprotein-associated phospholipase A2 (lp-PLA2), on inflammation and atherosclerotic formation in the low density lipoprotein receptor (LDLR)-deficient mice. METHODS: Six-week-old LDLR-deficient mice were fed an atherogenic high-fat diet for 17 weeks and then randomly divided into two groups. One group was administered darapladib (50 mg·kg(-1)·d(-1); po) for 6 weeks. The other group was administered saline as a control. Serum lipid levels were measured using the corresponding kits, and three inflammatory markers--interleukin-6 (IL-6), C reactive protein (hs-CRP), and platelet activating factor (PAF)--were determined using ELISA. Atherosclerotic plaque areas were stained with Sudan IV, and inflammatory gene expression at the lesions was evaluated using quantitative real-time PCR. RESULTS: The body weight and serum lipid level between the two groups were similar at the end of the dietary period. The serum lp-PLA2 activity, hs-CRP and IL-6 levels, however, were significantly reduced in the darpladib group. The inhibition of lp-PLA2 did not alter the serum PAF level. Furthermore, the plaque area, from the aortic arch to the abdominal aorta, was significantly reduced in the darpladib group. Additionally, the expression of inflammatory genes monocyte chemotactic protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) was significantly reduced at the lesions in the darapladib group. CONCLUSION: Inhibition of lp-PLA2 by darapladib decreases the inflammatory burden and atherosclerotic plaque formation in LDLR-deficient mice, which may be a new strategy for the treatment of atherosclerosis.
Authors: R Quarck; B De Geest; D Stengel; A Mertens; M Lox; G Theilmeier; C Michiels; M Raes; H Bult; D Collen; P Van Veldhoven; E Ninio; P Holvoet Journal: Circulation Date: 2001-05-22 Impact factor: 29.690
Authors: C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe Journal: N Engl J Med Date: 2000-10-19 Impact factor: 91.245
Authors: Steven Opal; Pierre-Francois Laterre; Edward Abraham; Bruno Francois; Xavier Wittebole; Stephen Lowry; Jean-Francois Dhainaut; Brian Warren; Thierry Dugernier; Angel Lopez; Miguel Sanchez; Ignace Demeyer; Luis Jauregui; Jose Angel Lorente; William McGee; Konrad Reinhart; Sascha Kljucar; Sonia Souza; John Pribble Journal: Crit Care Med Date: 2004-02 Impact factor: 7.598
Authors: Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett Journal: Circulation Date: 2004-02-02 Impact factor: 29.690
Authors: Michael Holzer; Gernot Schilcher; Sanja Curcic; Markus Trieb; Senka Ljubojevic; Tatjana Stojakovic; Hubert Scharnagl; Chantal M Kopecky; Alexander R Rosenkranz; Akos Heinemann; Gunther Marsche Journal: J Am Soc Nephrol Date: 2015-03-05 Impact factor: 10.121
Authors: Venkatesh Mani; Mark Woodward; Daniel Samber; Jan Bucerius; Ahmed Tawakol; David Kallend; James H F Rudd; Markus Abt; Zahi A Fayad Journal: Int J Cardiovasc Imaging Date: 2014-01-24 Impact factor: 2.357
Authors: Pauline Morigny; Doris Kaltenecker; Julia Zuber; Juliano Machado; Lisa Mehr; Foivos-Filippos Tsokanos; Hanna Kuzi; Chris D Hermann; Michael Voelkl; German Monogarov; Christoph Springfeld; Victor Laurent; Bernd Engelmann; Helmut Friess; Inka Zörnig; Achim Krüger; Jeroen Krijgsveld; Olga Prokopchuk; Søren Fisker Schmidt; Maria Rohm; Stephan Herzig; Mauricio Berriel Diaz Journal: J Cachexia Sarcopenia Muscle Date: 2021-08-23 Impact factor: 12.910